Question 1

What is combined oxidative phosphorylation defect type 27?

Accepted Answer

Combined oxidative phosphorylation defect type 27 is a very rare multisystem disorder caused by mutations in the CARS2 gene, which is essential for mitochondrial protein synthesis and energy production. Affected individuals typically present early in life with a combination of neurological, hepatic, and muscular involvement. The condition is inherited in an autosomal recessive pattern and is estimated to affect fewer than 1 in 1,000,000 people. Clinical manifestations are highly variable, and ongoing research and modern care continue to refine our understanding of its course.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 27?

Accepted Answer

Individuals with combined oxidative phosphorylation defect type 27 exhibit a wide range of clinical features. Neurologically, affected children present with hypotonia, bilateral tonic-clonic seizures, dystonia, chorea, myoclonus, and mental deterioration, with some showing evidence of global developmental delay and thinning of the corpus callosum. In many cases, after a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired skills. Additional features include feeding difficulties, failure to thrive, and visual impairment, while hepatic involvement is evident from microvesicular hepatic steatosis and hyperammonemia. Not all individuals experience all of these features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 27?

Accepted Answer

This condition is caused by mutations in the CARS2 gene, a critical gene for mitochondrial function that affects the synthesis of proteins required for energy production. It is inherited in an autosomal recessive manner, meaning that an affected individual has inherited a mutated copy of the gene from each parent. This condition is more common when parents share a common ancestor, as there is an increased chance both carry the same rare variant. Genetic counseling is recommended to help families understand the implications of this inheritance pattern and assess recurrence risks. Associated genes include CARS2.

Question 4

How is combined oxidative phosphorylation defect type 27 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 27 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 27?

Accepted Answer

combined oxidative phosphorylation defect type 27 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 27 diagnosed?

Accepted Answer

Definitive diagnosis of combined oxidative phosphorylation defect type 27 is achieved through molecular genetic testing that identifies pathogenic variants in the CARS2 gene. Clinical evaluation based on characteristic findings – such as hypotonia, seizures, and signs of liver involvement – in combination with family history supports the diagnostic process. As many of the symptoms overlap with other conditions, genetic testing is essential to confirm the diagnosis.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 27?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no specific foundational or FDA-approved treatments exist for combined oxidative phosphorylation defect type 27. Treatment is tailored to the individual and typically involves a multidisciplinary team to address the multisystem nature of the disorder. Regular surveillance is an essential part of long-term care, helping to identify complications early and guide adjustments in therapy. Patients should discuss treatment options with their healthcare team, and genetic counseling is recommended to support family planning and care coordination.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 27?

Accepted Answer

Individuals with combined oxidative phosphorylation defect type 27 may face various complications due to the multisystem nature of the disorder. Neurological issues like seizures and developmental regression can significantly impact daily life. Additionally, liver problems such as hyperammonemia and feeding difficulties can lead to serious health challenges. Regular monitoring and supportive care are essential to manage these complications.

Question 9

How does combined oxidative phosphorylation defect type 27 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 27 can be challenging for both patients and families. Affected individuals may require special care and support for feeding difficulties, developmental delays, and seizures. Families often need to coordinate with a multidisciplinary team to address the various symptoms and ensure that the patient receives comprehensive care. This can involve frequent medical appointments and therapies.

Question 10

What is the long-term outlook for someone with combined oxidative phosphorylation defect type 27?

Accepted Answer

The long-term outlook for individuals with combined oxidative phosphorylation defect type 27 varies widely. Some may experience a period of stabilization after initial developmental regression, while others might face ongoing challenges with motor skills and cognitive function. Access to specialized care and early intervention can improve outcomes, but it is important to remember that this is a lifelong condition requiring ongoing management.

Question 11

Are there any specialists that families should consult for combined oxidative phosphorylation defect type 27?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 27 should consider consulting specialists who are familiar with mitochondrial disorders. This may include neurologists, geneticists, and metabolic specialists who can provide tailored care and support. Regular follow-up with these experts is crucial for monitoring the condition and adapting management strategies as needed.

Kisho

combined oxidative phosphorylation defect type 27

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation defect type 27

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 27?

What are the symptoms of combined oxidative phosphorylation defect type 27?

What causes combined oxidative phosphorylation defect type 27?

How is combined oxidative phosphorylation defect type 27 inherited?

How rare is combined oxidative phosphorylation defect type 27?

How is combined oxidative phosphorylation defect type 27 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 27?

What complications can arise from combined oxidative phosphorylation defect type 27?

How does combined oxidative phosphorylation defect type 27 affect daily life for patients and families?

What is the long-term outlook for someone with combined oxidative phosphorylation defect type 27?

Are there any specialists that families should consult for combined oxidative phosphorylation defect type 27?

Explore clinical features

Recent Publications